Xenon Pharmaceuticals Inc.
XENE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001582313
In the last 90 days, Xenon Pharmaceuticals Inc. insiders filed 0 open-market purchases and 2 sales; 315 institutions reported holding it in 13F filings for Q2 2026, worth $6.10B in total; Duquesne Family Office is the only superinvestor holding it.
13F holders, Q2 2026
Institutional positions in Xenon Pharmaceuticals Inc. as of Jun 30, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 315
- +27 vs. Q1 2026
- Shares held
- 101.1M
- +5.07M (+5.3%) vs. Q1 2026
- Total value
- $6.10B
- +$538.5M (+9.7%) vs. Q1 2026
- New holders
- 49
- 126 more added
- Sold out
- 22
- 87 more reduced
2 institutions that held it in Q1 2026 haven't filed for Q2 2026 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q1 2026: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting XENE on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 315 | $6.10B |
| Q1 2026 | 290 | $5.80B |
| Q4 2025 | 245 | $3.78B |
| Q3 2025 | 219 | $3.39B |
| Q2 2025 | 206 | $2.60B |
| Q1 2025 | 206 | $2.58B |
| Q4 2024 | 209 | $2.99B |
| Q3 2024 | 203 | $2.95B |
| Q2 2024 | 213 | $2.89B |
| Q1 2024 | 220 | $3.16B |
| Q4 2023 | 204 | $3.32B |
| Q3 2023 | 181 | $2.10B |
| Q2 2023 | 175 | $2.36B |
| Q1 2023 | 163 | $2.19B |
| Q4 2022 | 159 | $2.38B |
| Q3 2022 | 154 | $2.09B |
| Q2 2022 | 151 | $1.73B |
| Q1 2022 | 132 | $1.50B |
| Q4 2021 | 130 | $1.49B |
| Q3 2021 | 118 | $521.7M |
| Q2 2021 | 103 | $620.0M |
| Q1 2021 | 91 | $590.0M |
Institutions, Q2 2026
Shares, value and share of portfolio for each institution holding Xenon Pharmaceuticals Inc.; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Westfield Capital Management Co LP | 1,507,294 | $91.0M | 0.30% | +105,811+7.5% | Added |
| Affinity Asset Advisors, LLC | 1,595,000 | $96.3M | 4.71% | −80,000−4.8% | Reduced |
| Deerfield Management Company, L.P. (Series C) | 1,615,696 | $97.5M | 1.02% | 00.0% | Unchanged |
| Two Sigma Investments, LP | 1,642,848 | $99.2M | 0.07% | +1,036,763+171.1% | Added |
| State Street Corp | 1,969,629 | $118.9M | 0.00% | +249,096+14.5% | Added |
| T. Rowe Price Investment Management, Inc. | 2,168,581 | $130.9M | 0.09% | +1,216,626+127.8% | Added |
| Capital International Investors | 2,361,639 | $142.5M | 0.03% | −313,088−11.7% | Reduced |
| JPMorgan Chase & Co | 2,617,360 | $157.4M | 0.01% | +693,750+36.1% | Added |
| Price T Rowe Associates Inc | 3,248,219 | $196.1M | 0.02% | +1,918,628+144.3% | Added |
| Jupiter Topco LLC | 4,186,519 | $252.7M | 0.10% | +4,186,519 | New |
| Driehaus Capital Management LLC | 4,418,557 | $266.7M | 1.55% | −73,096−1.6% | Reduced |
| Polar Capital Holdings Plc | 4,570,556 | $275.9M | 0.78% | +165,244+3.8% | Added |
| Avoro Capital Advisors LLC | 5,777,777 | $348.7M | 3.13% | 00.0% | Unchanged |
| BlackRock, Inc. | 7,522,482 | $454.1M | 0.01% | +1,882,364+33.4% | Added |
| FMR LLC | 9,647,998 | $582.4M | 0.03% | −1,170,493−10.8% | Reduced |
| Holocene Advisors, LP | 0 | $0 | 0.00% | −1,518,686−100.0% | Sold out |
| Commodore Capital LP | 0 | $0 | 0.00% | −825,000−100.0% | Sold out |
| MPM Oncology Impact Management LP | 0 | $0 | 0.00% | −588,706−100.0% | Sold out |
| Sofinnova Investments, Inc. | 0 | $0 | 0.00% | −305,216−100.0% | Sold out |
| Y-Intercept (Hong Kong) Ltd | 0 | $0 | 0.00% | −85,388−100.0% | Sold out |
| Atika Capital Management LLC | 0 | $0 | 0.00% | −59,900−100.0% | Sold out |
| LMR Partners LLP | 0 | $0 | 0.00% | −56,200−100.0% | Sold out |
| Qube Research & Technologies Ltd | 0 | $0 | 0.00% | −44,044−100.0% | Sold out |
| Calamos Advisors LLC | 0 | $0 | 0.00% | −30,374−100.0% | Sold out |
| SummitTX Capital, L.P. | 0 | $0 | 0.00% | −26,186−100.0% | Sold out |
| Sanders Morris Harris LLC | 0 | $0 | 0.00% | −21,500−100.0% | Sold out |
| Neo Ivy Capital Management | 0 | $0 | 0.00% | −13,710−100.0% | Sold out |
| Covalis Capital LLP | 0 | $0 | 0.00% | −10,000−100.0% | Sold out |
| Longaeva Partners L.P. | 0 | $0 | 0.00% | −6,250−100.0% | Sold out |
| DRW Securities, LLC | 0 | $0 | 0.00% | −5,461−100.0% | Sold out |
| Seeds Investor LLC | 0 | $0 | 0.00% | −3,423−100.0% | Sold out |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −3,468−100.0% | Sold out |
| Acadian Asset Management LLC | 0 | $0 | 0.00% | −677−100.0% | Sold out |
| MAI Capital Management | 0 | $0 | 0.00% | −392−100.0% | Sold out |
| Root Financial Partners, LLC | 0 | $0 | 0.00% | −40−100.0% | Sold out |
| Golden State Equity Partners | 0 | $0 | 0.00% | −35−100.0% | Sold out |
| Twin Peaks Wealth Advisors, LLC | 0 | $0 | 0.00% | −32−100.0% | Sold out |
| Janus Henderson Group PLC | – | – | – | – | Not filed |
| CWM, LLC | – | – | – | – | Not filed |